Skip to main content
Clinical Trials/NCT02175641
NCT02175641
Completed
Not Applicable

Peer-Led Healthy Lifestyle Program in Supportive Housing Agencies

Washington University School of Medicine1 site in 1 country314 target enrollmentJuly 2015
ConditionsObesity

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
Washington University School of Medicine
Enrollment
314
Locations
1
Primary Endpoint
Clinically Significant Weight Loss
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This goal of this randomized controlled effectiveness trial is to compare the effectiveness of a peer-led health lifestyle intervention (Peer GLB) versus usual care services in supportive housing agencies in New York City and Philadelphia serving diverse clients with serious mental illness who are overweight or obese. The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and that has been shown to help people achieve clinically significant weight loss (equal to or greater than 5% weight loss of initial weight). The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).

We plan to enroll 300 clients with serious mental illness who are overweight/obese (BMI equal to or greater than 25) from our two supportive housing agencies. Clients will be randomized to either the Peer-led healthy lifestyle intervention or usual care conditions. The primary outcome for this study is achieving clinically significant weight loss (equal to or greater than 5% weight loss from baseline weight) at 12 and 18 months post randomization. The secondary outcomes for this study include overall reductions in weight, waist circumference, blood pressure, and improvements in physical activity, self-efficacy, recovery and health-related quality of life. Repeated assessments will be at baseline, 6, 12 and 18 month post randomization.

Primary Hypothesis: Peer GLB participants will have a higher proportion of persons achieving clinically significant weight loss (equal to or greater than 5% weight loss) at 12 and 18 months than UC participants.

Secondary Hypothesis: At 6, 12, and 18 months post-randomization, there will be significant reductions in average weight, waist circumference, blood pressure, and significant improvements in physical activity, self-efficacy, recovery, and health-related quality of life in Peer GLB compared to UC.

Registry
clinicaltrials.gov
Start Date
July 2015
End Date
July 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Leopoldo J. Cabassa

Associate Professor

Washington University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Male or female,18 years of age or older, of any race/ethnicity, who are English and/or Spanish speakers.
  • Chart diagnosis of a serious mental illness (SMI; e.g., schizophrenia, bipolar disorder, schizoaffective disorders, major depression).
  • Overweight/obese as determined by a Body Mass Index (BMI) equal to or greater than 25 (kg/m2) at the time of recruitment.
  • Able and willing to give informed consent and participate in the intervention.
  • Received a medical clearance from a primary care or medical provider to participate in light-to-moderate physical activity (e.g., 150 minutes a week of brisk walking).

Exclusion Criteria

  • Need for detoxification services at the time of recruitment.
  • Pose a danger to self or others at the time of recruitment.
  • Have medical conditions that contraindicate their participation in a healthy lifestyle program focusing on weight loss and physical activity, such as active cancer treatment, liver failure, history of anorexia nervosa, cardiovascular event \[e.g., unstable angina, myocardial infraction\] within the past 6 months, untreated exercise- induced asthma, walking limitations preventing participation in exercise, and pregnant or planning a pregnancy during study period.
  • Fail a capacity-to-consent questionnaire.
  • Cognitive impairment as detected by the Mini-Cog Examination

Outcomes

Primary Outcomes

Clinically Significant Weight Loss

Time Frame: Baseline to 18 Months

Percentage of participants that achieve equal to or greater than 5% weight loss in lb from baseline at 12 and 18th months

Secondary Outcomes

  • Overall Reduction in Weight in lb From Baseline to 6, 12 and 18 Months(At study endpoint (18 months).)
  • Change From Baseline in Recovery Using the Recovery Assessment Scale (RAS).(At study endpoint (18 months).)
  • Overall Reduction in Waist Circumference Measures to the Nearest cm From Baseline to 6, 12 and 18 Months(At study endpoint (18 months).)
  • 6-Minutes Walking Test(At study endpoint (18-months).)
  • Overall Reductions in Systolic Blood Pressure From Baseline, 6, 12 and 18 Months(At study endpoint (18 months).)
  • Self-Efficacy for Exercise(At study endpoint (18 months).)
  • Health-related Quality of Life(At study endpoint (18-months).)

Study Sites (1)

Loading locations...

Similar Trials